AI Insight
This global study of 188 countries from 2000-2023 found that meningitis disease burden declined by approximately 5% annually, with significant associations between vaccine introduction and reduced disability rates. The Haemophilus influenzae type b (Hib) vaccine was associated with a 6.7% reduction and pneumococcal conjugate vaccine (PCV) with a 4.8% reduction in disability-adjusted life years globally, with substantially larger effects (approximately 10-17%) observed in high-burden regions, particularly the African meningitis belt.
Why it matters
The findings provide quantitative evidence supporting prioritized vaccine deployment in endemic regions where impact is greatest, potentially informing global immunization policy and resource allocation. The study demonstrates that targeted vaccination programs in high-burden areas could maximize public health returns and reduce health disparities.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Background: Meningitis remains a major cause of global morbidity and mortality. We aimed to quantify the association between vaccine introduction and meningitis-related disability-adjusted life year (DALY) rates globally and across high-burden regions from 2000 to 2023. Methods: We conducted a longitudinal panel study of 188 countries using health metrics from the Global Burden of Disease study and WHO vaccine data. We estimated associations using two-way fixed effects regression models, adjusting for GDP and healthcare access. Analyses were stratified by baseline burden and included the African meningitis belt. Findings: Globally, meningitis DALY rates declined by 4.97% per year (p<0.0001). Introduction of the Hib vaccine was associated with a 6.7% reduction in DALY rates, and PCV with a 4.8% reduction. In high-burden countries, both vaccines were associated with larger reductions (~10%), while no significant effects were detected in low-burden settings. In the African meningitis belt, PCV introduction was associated with a substantial 16.8% reduction in DALY rates (p<0.0001). No significant global association was observed for meningococcal vaccines. Interpretation: Global declines in meningitis burden are strongly associated with Hib and PCV scale-up, with the greatest benefits in high-burden settings. These findings support prioritized vaccine deployment in endemic regions to maximize public health impact. However, the presence of pre-treatment trends for Hib suggests these estimates represent vaccine-associated population-level changes rather than strictly causal effects.